No Data
No Data
Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) Price Is Right But Growth Is Lacking After Shares Rocket 36%
As of August 9, 2024, the total number of shareholders for Guangdong Hybribio Biotech (300639.SZ) is 34,097.
Guangdong Hybribio Biotech (300639.SZ) stated on the investor interaction platform on August 13th that as of August 9th, 2024, the total number of shareholders in the company was 34,097.
Guangdong Hybribio Biotech (300639.SZ): Its medical laboratory has the ability to test for monkeypox virus.
On August 13th, Guandong Hybribio Biotech (300639.SZ) stated on its investor relations platform that the company's medical laboratory has the ability to test for monkeypox virus. The company has independently developed a Monkeypox Virus Real-time PCR Kit (fluorescence PCR method) and has obtained CE certification. However, the product has not yet obtained a domestic medical instrument registration certificate. The invention patents related to monkeypox virus include "A kind of monkeypox virus pseudovirus particle and its preparation method" and "A method for simultaneously detecting and identifying monkeypox virus type I, ..."
Is Guangdong Hybribio BiotechLtd (SZSE:300639) Using Debt In A Risky Way?
Guangdong Hybribio Biotech (300639.SZ): has repurchased 0.39% of its shares.
Guangdong Hybribio Biotech (300639.SZ) announced on July 31 that as of July 31, 2024, the company has cumulatively repurchased 2,505,100 shares, accounting for 0.39% of the current total share capital of the company (excluding the shares in the company's repurchase special securities account); the highest fill price for repurchase is RMB 4.81/share, and the lowest fill price is RMB 4.37/share; the total amount of funds paid is RMB 11,347,431.03 yuan (including transaction costs). This share repurchase program complies with relevant laws and regulations and the company's share repurchase plan.
Guangdong Hybribio Biotech (300639.SZ): In July, the company and its subsidiaries received a total of 3 authorized invention patents.
On July 31st, Gelonhui reported that Guangdong Hybribio Biotech (300639.SZ), along with its subsidiaries, obtained a total of three authorized invention patents in July 2024. The patents include a microfluidic chip for live cell sorting, a primer and probe combination for detecting 16 pathogenic mutations of the SLC22A5 gene, and a set of primers and reagents based on nucleic acid mass spectrometry for simultaneous detection of folate and nutrient metabolism gene SNP sites in a single tube.
No Data